“In vivo inhibitory effect of suberoylanilide hydroxamic acid combined with sorafenib on human hepatocellular carcinoma cells”, Braz. J. Pharm. Sci., vol. 56, p. e18254, Dec. 2020, doi: 10.1590/s2175-97902019000318254.